VCM
BIOTU

Vivaldi Capital Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Vivaldi Capital Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$101K – 360
2021
Q2 		$101K Hold
10,000
– – 0.02% 314
2021
Q1 		$99K Buy
+10,000
New +$103K 0.02% 347

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CCFM
Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Vivaldi Capital Management's BIOTU Position: Q3 2021 in Review

Vivaldi Capital Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q3 2021, closing a stake of 10,000 shares — an estimated $101K sold.

Vivaldi Capital Management first reported a position in BIOTU in Q1 2021 and held it in 2 quarters. The position peaked at $101K in Q2 2021. 34 funds tracked by Wall St. Rank hold BIOTU as of Q3 2021.

  • Vivaldi Capital Management reported no remaining Biotech Acquisition Company Unit position as of Q3 2021 after selling out during the quarter.
  • Vivaldi Capital Management sold 10,000 Biotech Acquisition Company Unit shares in Q3 2021, an estimated $101K.
  • Vivaldi Capital Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 2 quarters.
  • Vivaldi Capital Management's Biotech Acquisition Company Unit position peaked at $101K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q3 2021.

Based on Vivaldi Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.